Schroder Investment Management Group Seagen Inc. Transaction History

Schroder Investment Management Group

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$191.51 - $216.16 $220,428 - $248,800	-1,151 Reduced 14.41%	6,837 $1.45 Million
Q2 2023 Aug 11, 2023	SELL	$187.64 - $206.25 $148,235 - $162,937	-790 Reduced 9.0%	7,988 $1.54 Million
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $47,208 - $75,139	370 Added 4.4%	8,778 $1.78 Million
Q4 2022 Feb 10, 2023	BUY	$117.37 - $139.17 $15,962 - $18,927	136 Added 1.64%	8,408 $1.08 Million
Q3 2022 Nov 10, 2022	SELL	$135.27 - $180.11 $10,415 - $13,868	-77 Reduced 0.92%	8,272 $1.13 Million

Q2 2022 Aug 11, 2022	BUY	$108.81 - $179.33 $399,659 - $658,679	3,673 Added 78.55%	8,349 $1.5 Million
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $203,217 - $268,187	1,699 Added 57.07%	4,676 $662,000
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $20,085 - $23,944	-141 Reduced 4.52%	2,977 $505,000
Q2 2021 Aug 13, 2021	BUY	$135.08 - $161.1 $104,011 - $124,047	770 Added 32.79%	3,118 $492,000
Q1 2021 May 17, 2021	SELL	$137.51 - $190.8 $176,425 - $244,796	-1,283 Reduced 35.33%	2,348 $326,000
Q4 2020 Feb 16, 2021	BUY	$164.63 - $211.93 $597,771 - $769,517	3,631 New	3,631 $636,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Schroder Investment Management Group, based on Form 13F filings with the SEC.

Stay updated on Schroder Investment Management Group with notifications on news.